On June 19, 2025, at the headquarters building of Douzheng Biotechnology in Changsha, Lishan Biotech and leading domestic CRO enterprise Douzheng Biotechnology officially reached a strategic cooperation to jointly promote the clinical trials of Lishan Biotech's independently developed live biopharmaceutical (LBP) in the field of inflammatory bowel disease (IBD). This cooperation marks a new stage in the clinical exploration of live biopharmaceutical therapy, which is expected to provide safer and more effective innovative therapies for IBD patients worldwide.   Innovative treatment for IBD using LBP biopharmaceuticals Live Biotherapeutic Products (LBP) is an emerging therapy that utilizes live microorganisms to regulate the human microbiota for the treatment of diseases, and is considered the "third generation therapy" after small molecule...

On the morning of May 15, 2025, the Zhangjiang China Medicine Valley Conference Room welcomed a team of evaluation experts led by the Pudong New Area Science and Technology Commission to assess the digital transformation achievements of Shanghai Lishan Biopharmaceutical Co., Ltd. on site. Dr. Zhu Chaoyu, General Manager of Lishan Biotechnology, along with Ms. Guo Yushan, Manager of the Research Project Management Department, Dr. Wang Mengya, Deputy Director of Zhangjiang Live Biopharmaceutical R&D Center, Ms. Song Junmei, Deputy General Manager, Mr. Yang Weikang, Manager of the Production Quality Department, and other team members, participated in the on-site review, which was chaired and reported by Ms. Guo Yushan. Starting from September 1, 2024, Lishan Biotechnology has completed the upgrade and deployment of the Su...

  The change of time sequence gave birth to Huazhang, and spring and Jingming brought good news. On May 9th, 2025, Lishan Biotech Dr. Chen Weijie, Chairman, was awarded the VBEF Annual Innovation Entrepreneur AwardLishan Biotechnology, with its cutting-edge breakthroughs and innovative value in the field of live biopharmaceuticals, has successfully made it onto the list of "2025 Future Medical Top 100" on Arterial Network! This is not only a tribute to the scientific research team's perseverance, but also a full affirmation of the "AI+live biopharmaceutical" innovation track strategy.   As a benchmark for innovation in the healthcare industry, the "Future Medical Top 100" always focuses on non listed companies with the greatest growth potential. The selection of Lishan Biotechnology marks the industry's recognition of its leading position in ...

On the afternoon of March 21, 2025, Dr. Chen Weijie, Chairman of Shanghai Lishan Biopharmaceutical Co., Ltd., and Dr. Zhu Chaoyu, General Manager of Keyin Wisdom (Shanghai) Pharmaceutical Co., Ltd., were invited to the Punan Branch of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine to hold a seminar on medical industry integration services, to deeply explore cooperation in scientific research, clinical practice, testing, and AI platforms. This conference, chaired by Fan Jincheng, Vice President of the Shanghai Modern Service Industry Federation, gathered representatives from multiple member units of the Big Health Service Committee, building an important bridge for the coordinated development of the big health industry.   At the beginning of the meeting, Lei Zhen, Secretary of the Party Committee of...